Notice NOT-OD-22-168 from the NIH Guide for Grants and Contracts

Notice NOT-NR-22-015 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-22-192 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports applications to develop and implement a Clinical Coordinating Center (CCC) for investigator-initiated multi-site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website.This FOA will utilize a bi-phasic, milestone-driven cooperative agreement mechanism of award and runs in parallel with a companion FOA that encourages applications for a collaborating Data Coordinating Center (PAR-22-NNN). The objective of the CCC application is to present the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes it. The application should address project management, subject recruitment and retention, performance milestones, scientific conduct of the trial, and dissemination of results. Both a CCC application and a collaborating Data Coordinating Center (DCC) application must be submitted on the same application due date for consideration by NHLBI. Applicants are strongly encouraged to contact the appropriate Scientific/Research contact prior to submitting an application.

Funding Opportunity PAR-22-193 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports applications for a collaborating Data Coordinating Center (DCC) for investigator-initiated multi-site clinical trials including efficacy, comparative effectiveness, pragmatic and/or implementation research clinical trials. These trials may include ones that test different therapeutic, behavioral, and/or prevention strategies. Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website.This FOA will utilize a cooperative agreement mechanism of award and runs in parallel with a companion FOA (PAR-22-NNN) that encourages applications for a collaborating Clinical Coordinating Center (CCC). The objective of the DCC application is to present a comprehensive plan to provide overall project coordination, administration, data management, and biostatistical support for the clinical trial proposed in the collaborating CCC application.Both a DCC application and a collaborating CCC application must be submitted on the same application due date for consideration by NHLBI.

Notice NOT-AT-23-002 from the NIH Guide for Grants and Contracts

Notice NOT-GM-22-038 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-22-190 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites qualified academic or research institutions to apply for funding support to purchase advanced equipment that will enhance and modernize research-supporting operations of biomedical research facilities. Targeted are laboratory research core facilities, animal research facilities, and other similar shared-use research spaces. The goal of this FOA is to strengthen research-auxiliary activities of biomedical research facilities and to enhance the efficiency of their operations. The FOA does not support the purchase of scientific research instruments or their components, nor components of building-level infrastructure equipment that indirectly support research activities.

Funding Opportunity RFA-DA-23-041 from the NIH Guide for Grants and Contracts. Identify multi-level solutions for patients on long-term opioid treatment who are exhibiting harmful opioid behaviors, but do not meet criteria for OUD. Patients with lived experience should consult on these projects. A resource center is also needed to clinically identify this ambiguous population and provide metrics for the field for balanced assessment of opioid risks and harms. The resource center would convene a panel of stakeholders and bioethicists to guide these efforts. NEPS Concept# 2393

Funding Opportunity RFA-DA-23-042 from the NIH Guide for Grants and Contracts. Identify multi-level solutions for patients on long-term opioid treatment who are exhibiting harmful opioid behaviors, but do not meet criteria for OUD. Patients with lived experience should consult on these projects. A resource center is also needed to clinically identify this ambiguous population and provide metrics for the field for balanced assessment of opioid risks and harms. The resource center would convene a panel of stakeholders and bioethicists to guide these efforts.

Funding Opportunity RFA-MH-22-280 from the NIH Guide for Grants and Contracts. The goal of this initiative is to study the role of epigenetic mechanisms regulating HIV CNS (central nervous system) latency and neuropathogenesis in brain derived cells such as macrophages, microglia and astrocytes using novel single cell technologies. Thus this FOA will encourage studies of the role of epigenetic mechanisms regulating HIV CNS latency and neuropathogenesis in brain derived cells such as macrophages and microglia using novel single cell technologies.

Funding Opportunity RFA-MH-22-281 from the NIH Guide for Grants and Contracts. The goal of this initiative is to study the role of epigenetic mechanisms regulating HIV CNS (central nervous system) latency and neuropathogenesis in brain derived cells such as macrophages, microglia and astrocytes using novel single cell technologies. Thus this FOA will encourage studies of the role of epigenetic mechanisms regulating HIV CNS latency and neuropathogenesis in brain derived cells such as macrophages and microglia using novel single cell technologies.

Funding Opportunity RFA-DK-22-021 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for studies of type 1 diabetes etiology and pathogenesis using data and samples from clinical trials and studies. This opportunity is intended to fund investigative teams collaborating to answer important questions about disease mechanisms leading to improved prevention of type 1 diabetes.

Funding Opportunity RFA-EB-22-001 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits applications for team-centric development and validation of innovative non-invasive imaging technologies that could have a transformative impact on the study of brain function/connectivity. Applications are expected to turn a novel concept into a functional prototype using this phased grant mechanism. The feasibility should be established by the end of its first phase and serve as a foundation for the transition to its second phase. Fully developing the technology into a functional prototype and validating it by in-vivo animal or human function/connectivity imaging are anticipated in the second phase. The research plan should provide a realistic timeline and tangible milestones to support the proposed development effort. Awards will be integrated into the BRAIN Non-Invasive Imaging Consortium, as a coordinated network on brain function/connectivity imaging.

Funding Opportunity RFA-AG-23-021 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications to expand the content, design, and implementation of research infrastructure funded under FOA RFA-AG-18-012 Mobile Monitoring of Cognitive Change (U2C), also known as the Mobile Toolbox (MTB) Project. The expansion aims to (1) add assessments on mobile devices of non-cognitive socioemotional psychological functions, health states, and contextual factors that may modify cognitive performance; and (2) enable widespread dissemination and support for use of the tools developed for monitoring of age, state, context, or health condition-related changes in cognitive and non-cognitive abilities on mobile devices. The expanded MTB efforts must include the development, or support for development, of applications on the two leading smartphone platforms, the Android and iOS platforms, and the validation of new tests and items to be used on the platforms by age groups ranging from 20 to 85. The goals of this expanded platform are to support data collection efforts from participants enrolled in the project awarded through this FOA, as well as other NIH-funded studies through fiscal year 2027, and to enable the widespread sharing of both the collected data and the test instruments. Thus, research supported through this FOA will continue the development of the MTB platform as described above, with expanded content, wider dissemination, the ability to add study-specific measures, and leverage a shared data processing backend. Additionally, supported research will aim to bring to maturity a model for future cost recovery, via standardized subcontracting terms, conditions, and costs, that will allow the platform to remain continuously updated and available for widespread use as the easiest means for researchers to collect real-time, real-world, temporally extended data most relevant to the early detection and study of Alzheimers disease (AD) and AD-related dementias (ADRD).

Notice NOT-MD-22-012 from the NIH Guide for Grants and Contracts

Notice NOT-OD-22-167 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-NS-23-014 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) seeks applicants experienced in the isolation and sequencing of RNA from brain-derived extracellular vesicles to develop a research resource for the Accelerating Medicines Partnership in Parkinson's Disease (AMP PD). Approximately 2400 blood samples will be provided for this project from existing Parkinson's disease and normal control cohorts that already have longitudinal clinical and sequencing data that is publicly available to interested researchers. It is intended that this resource will become a part of the AMP PD Knowledge Platform, where it will be broadly shared with the research community.

Notice NOT-MH-22-245 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DA-23-045 from the NIH Guide for Grants and Contracts. The need to rapidly develop methods to assess the prevalence / health impact of emerging illicit drugs has never been greater. Illicit chemists are marketing potent drugs of abuse taken from deep wells of scientific and patent literature, which we can expect to continue to yield new drugs for many years. Over the last few years, fentanyl/fentalogs (fentanyl-related opioids) have flooded the illicit opioid market, which has complicated patient stabilization / harm reduction, and caused mortality rates to skyrocket. Even understanding the drugs being used is difficult due to unstandardized analytical methods, and urine test strip kit variabilities. When test strips do detect fentalogs they simply indicate fentanyl and clinicians base treatment on this homogenous grouping. However, it is unclear that the addictive or mortality risk of fentalogs are generalizable. Initially fentanyl was reported to be long-lasting and poorly antagonizable, but such reports diminished when carfentanil, an ultrapotent and long-lasting fentalog, diminished in drug supplies. Now, ultrapotent "nitazene" opioids are on the market and a lack of validated analytical protocols and standards, has meant these drugs are over-looked in most jurisdictions. Nitazene urine test strips do not yet exist and so clinicians are ill-equipped to recognize nitazenes and respond appropriately. Users certainly do not know whether nitazenes (or fentalogs) are illicit purchased drugs. This FOA promotes development and distribution of tools to detect nitazenes in the necessary range of settings needed to enable appropriately calculated responses. Additionally, this RFA builds-in funds to allow awardees to rapidly bring their discoveries and expertise to bear on the future generations of threats that are surely coming

Notice NOT-OD-22-175 from the NIH Guide for Grants and Contracts